Everolimus Novartis

Current Opinion in Investigational Drugs

Volumn 2, Issue 9, 2001, Pages 1220-1234

  Dumont, F J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG TOLERABILITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG TRANSPLANTATION; LYMPHOCYTOPENIA; MONOTHERAPY; NONHUMAN; PROPHYLAXIS; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXICITY TESTING; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034822666     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Rapamycin - Distribution, pharmacokinetics, and therapeutic range investigations
2. American Home Products announces UK patent infringement judgment against Novartis' rapamycin derivative
3. Novartis announces favorable decision in patent infringement action brought against its Certican drug by AHP
4. Immunosuppressive agents in organ transplantation: Past, present, and future
5. Mechanism of action of the immunosuppressant rapamycin
6. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine
7. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation
8. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats
9. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin
10. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo
11. SDZ RAD, a new rapamycin derivative. Synergism with cyclosporine
12. The macrolide SDZ RAD is efficacious in a nonhuman primate model of allotransplantation
13. The immunosuppressive macrolide RAD inhibits growth of human Epstein- Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
14. Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD
15. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation
16. Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry
17. SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts
18. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin
19. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates
20. Isolation from pig liver microsomes, identification by tandem mass spectrometry and in vitro immunosuppressive activity of an SDZ-RAD 17,18,19,20,21,22-tris-epoxide
21. Prevention of small airway obliteration in a swine heterotopic lung allograft model
22. Immunosuppressive therapies after heart transplantation: Best, better, and beyond
23. Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability
24. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative
25. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
26. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients
27. SDZ RAD inhibits cold ischemia-induced vascular remodeling
28. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: Potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment
29. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients
30. Suppression of acute rejection in allogeneic rat lung transplantation: A study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine
31. LC/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood
32. In vitro biotransformation of SDZ RAD: A new immunosuppressive macrolide in human liver microsomal preparations
33. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model
34. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model
35. Chemical modification of rapamycin: The discovery of SDZ RAD
36. Structural elucidation by electrospray mass spectrometry: An approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD
37. Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin
38. The effect of SDZ-RAD on ongoing chronic rejection in rat renal allograft
39. The sirolimus derivative SDZ-RAD inhibits rat and human mesangial cell proliferation in vitro
40. UK Court of Appeal decides in favour of Novartis in patent action against AHP: Investigational transplant drug Certican does not infringe AHP patent: Decision important for patients and for research-based pharmaceutical industry in general
41. Analyst Report: Novartis (Switzerland/Pharma)
42. The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD
43. Novartis announces positive trial results for two novel transplantation drugs
44. Novartis R & D investor seminar, Basel
45. Novartis' Certican patent upheld by European Patent Office
46. Annual Report 2000: Review of operations - Pharmaceuticals - pipeline
47. Treatment of transplant rejection: Are the traditional immunosuppressants good enough?
48. Certican, a proliferation signal inhibitor, effective in preventing acute rejection in renal transplant recipients
49. Long-term pharmacokinetics of the metabolites of SDZ RAD and cyclosporine in transplant recipients
50. Transplant 2001, New Immunosuppressive Drugs, Chicago, USA
51. Metabolism of sirolimus and its derivative everolimus by cytochrome p450 3A4: Insights from docking, molecular dynamics, and quantum chemical calculations
52. Novartis: Best foot forward
53. Differential influence of Neoral versus Sandimmune on everolimus pharmacokinetics: A clinically relevant drug interaction
54. Rifampin (a p450 enzyme-inducer) significantly increases the clearance of everolimus: Implications for coadministration
55. RAD (everolimus) pharmacokinetics in de novo renal transplant patients: Dose-proportional, stable exposure over 6 months
56. RAD (everolimus) pharmacokinetics are unaltered with full-dose versus reduced-dose cyclosporine
57. A one-year, multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding study to evaluate the safety, tolerability and pharmacokinetics of RAD in de novo liver transplant recipients
58. Influence of renal and hepatic impairment on everolimus pharmacokinetics: Are dose adjustments necessary?
59. One year results of a multicenter, open-label trial on safety and efficacy of Certican (RAD) used in combination with Simulect, corticosteroids, and full or reduced dose Neoral in renal transplantation
60. Exposure-response relationships for everolimus in de novo renal transplantation: Toward defining a therapeutic range
61. North/South American, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral® and corticosteroids
62. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
63. High-throughput analysis of everolimus (RAD001) and cyclosporin A (CsA) in whole blood by liquid chromatography/mass spectrometry using a semi-automated 96-well solid-phase extraction system
64. Chronic rejection
65. The target of rapamycin (TOR) proteins
66. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates
67. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
68. International, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral® and steroids
69. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution
70. Lung transplantation at the turn of the century
71. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD
72. A high-capacity quantitative mouse model of drug-mediated immunosuppression based on rejection of an allogeneic subcutaneous tumor
73. FTY-720
74. Obliterative lesions in a heterotopic bronchial xenograft model - A preliminary study
75. 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats
76. RAD reduces compensatory renal graft hypertrophy in a rat model of chronic rejection
77. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD
78. Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD
79. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells
80. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine
81. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
82. Longitudinal influence of everolimus on cyclosporine assessed over 6 months in two blinded de novo kidney transplant trials
83. Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection
84. High-throughput semi-automated 96-well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood
85. Opus Diagnostics Inc. entered into an agreement with Novartis Pharma AG for Opus to develop and market an assay to monitor Certican™ (everolimus) blood levels
86. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients
87. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration
88. Pharmacokinetics and tolerability of 40-O-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients
89. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection
90. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: Risk factors, incidence, progression, and management
91. Therapeutic drug monitoring of sirolimus: Correlations with efficacy and toxicity
92. Increase in blood lipids in de novo renal transplant patients following Certican™ (RAD) administration is manageable and not associated with increased cardiovascular risk
93. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
94. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
95. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain
96. Use of sirolimus in kidney transplantation
97. Cytomegalovirus infection and cardiac allograft vasculopathy
98. Pharma cokinetics and tolerability of RAD in pediatric renal transplant patients